Enzyme provides promising path to degenerative joint diseases cure (Allegra)

Medical Xpress / Yale University / Bone Research ^ | Nov. 13, 2025 | John Ready / Guiwu Huang et al

[ConservativeMind]

Degenerative joint diseases like osteoarthritis and intervertebral disk degeneration are conditions that affect millions of people worldwide, leading to pain and reduced mobility.

A study found that cytosolic phospholipase A2 (cPLA2) is an important enzyme. It plays a key role in inflammation and cartilage breakdown. The study suggests that cPLA2 could be a possible target for treating joint diseases.

Osteoarthritis and intervertebral disk degeneration are conditions that slowly break down cartilage in joints and disks in the spine. This leads to pain, inflammation, and impaired function that worsens over time.

Members used advanced methods to examine the relationship between cPLA2 and joint degeneration. Notably, they investigated a common antihistamine, fexofenadine, as a potential cPLA2 inhibitor.

Cytosolic phospholipase A2: regulator of degenerative joint diseases The study revealed several critical insights:

—Role in damaged cartilage cells: cPLA2 is the main driver of cartilage decay. This enzyme becomes too active in certain cartilage cells. These cells are already likely to break down and show signs of aging.

—Keeping cartilage healthy: Removing cPLA2 through genetics and blocking it with drugs greatly lowered inflammation. This also stopped cartilage cells from breaking down and aging. This means this gene is crucial for keeping cartilage cells healthy, and stopping its action could protect the cartilage from damage.

—Potential of fexofenadine: Fexofenadine blocked cPLA2 effectively by reducing inflammation and prevented cartilage cells from aging.

These findings underscore the potential of targeting cPLA2 as a disease-modifying treatment strategy for degenerative joint diseases. The researchers believe that blocking cPLA2 can help with inflammation and chondrocyte aging—the main causes of cartilage damage.

Pharmacological studies using fexofenadine further supported the genetic findings. Fexofenadine treatment reduced cartilage degradation as well as both inflammation and age-related deterioration.

---

TOPICS: Health/Medicine
KEYWORDS: back; disk; enzyme; inflammation

[ConservativeMind]

Fexofenadine (Allegra) is one of many antihistamines available without a prescription.

If you need such a drug and have these other issues, consider switching.

It apparently made a big difference with degenerative back and joint cell tests.

[ConservativeMind]

The “Take Charge Of Your Health” Ping List
This high volume ping list is for health articles and studies which describe something you or your doctor, when informed, may be able to immediately implement for your benefit.

Email me to get on either the “Common/Top Issues” (20 - 25% fewer pings) or “Everything” list.

[sauropod]

bkmk

[tired&retired]

Why take an antihistamine that blocks histamine receptors when you can take diamine oxidase enzyme that actually degrades the histamines in the body?

[tired&retired]

Cytosolic phospholipase A2 (cPLA2) is an enzyme involved in inflammation by releasing arachidonic acid, a precursor for inflammatory mediators.

Arachidonic acid is an omega-6 polyunsaturated fatty acid found in cell membranes that is involved in cell signaling, inflammation, and neurological functions. It is a precursor in the formation of leukotrienes, prostaglandins, and thromboxanes.

Arachidonic acid is a key inflammatory intermediate and can also act as a vasodilator.

[jonrick46]

Bookmark

[Salamander]

Okay missy.

What do you know about this?!?

🤔